Tangeretin and its metabolite 4′‐hydroxytetramethoxyflavone attenuate EGF‐stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K
Open Access
- 30 December 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (8) , 1781-1791
Abstract
BACKGROUND AND PURPOSE The mechanisms by which the dietary compound tangeretin has anticancer effects may include acting as a prodrug, forming an antiproliferative product in cancer cells. Here we show that tangeretin also inhibits cell cycle progression in hepatocytes and investigate the role of its primary metabolite 4′‐hydroxy‐5,6,7,8‐tetramethoxyflavone (4′‐OH‐TMF) in this effect.EXPERIMENTAL APPROACH We used epidermal growth factor (EGF)‐stimulated rat hepatocytes, with [3H]‐thymidine incorporation into DNA as an index of progression to S‐phase of the cell cycle, and Western blots for phospho‐proteins involved in the cell signalling cascade.KEY RESULTS Incubation of tangeretin with microsomes expressing CYP1A, or with hepatocytes, generated a primary product we identified as 4′‐OH‐TMF. Low micromolar concentrations of tangeretin or 4′‐OH‐TMF gave a concentration‐dependent inhibition of EGF‐stimulated progression to S‐phase while having little effect on cell viability. To determine whether time for conversion of tangeretin to an active metabolite would enhance the inhibitory effect we used long pre‐incubations; this reduced the inhibitory effect, in parallel with a reduction in the concentration of tangeretin. The EGF‐stimulation of hepatocyte cell cycle progression requires signalling through Akt/mTOR/p70S6K kinase cascades. The tangeretin metabolite 4′‐OH‐TMF selectively inhibited S6K phosphorylation in the absence of significant inhibition of upstream Akt activity, suggesting an effect at the level of mTOR.CONCLUSIONS AND IMPLICATIONS Tangeretin and 4′‐OH‐TMF both inhibit cell cycle progression in primary hepatocytes. The inhibition of p70S6K phosphorylation by 4′‐OH‐TMF raises the possibility that inhibition of the mTOR pathway may contribute to the anticancer influence of a flavonoid‐rich diet.Keywords
This publication has 29 references indexed in Scilit:
- mTOR and cancer: many loops in one pathwayCurrent Opinion in Cell Biology, 2010
- mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesisProceedings of the National Academy of Sciences, 2010
- Differential Expression of Biomarkers in Men and WomenSeminars in Oncology, 2009
- Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling PathwayCancer Research, 2009
- mTOR signaling at a glanceJournal of Cell Science, 2009
- Cultured rat hepatocytes upregulate Akt and ERK in an ErbB-2-dependent mannerAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolismBreast Cancer Research, 2008
- Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?Seminars in Cancer Biology, 2007
- Tangeretin inhibits extracellular‐signal‐regulated kinase (ERK) phosphorylationFEBS Letters, 2005
- PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survivalHepatology, 2002